Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, Cherkasov A.

Mol Cancer Ther. 2016 Dec;15(12):2936-2945. Epub 2016 Oct 7.

2.

Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.

Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, Ban F, Hsing M, Adomat H, Lallous N, Andre C, Jonadass JP, Zoubeidi A, Young RN, Guns ET, Rennie PS, Cherkasov A.

Chem Biol. 2014 Nov 20;21(11):1476-85. doi: 10.1016/j.chembiol.2014.09.012.

3.

In vitro assessment of clevidipine using the profilin1 hypertensive mouse model.

Hassanain HH, Hassona MD, Puente EG, Sun C, Abouelnaga ZA, Tulman DB, Bergese SD.

Pharmaceuticals (Basel). 2013 Apr 29;6(5):623-33. doi: 10.3390/ph6050623.

4.

Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.

Li H, Hassona MD, Lack NA, Axerio-Cilies P, Leblanc E, Tavassoli P, Kanaan N, Frewin K, Singh K, Adomat H, Böhm KJ, Prinz H, Guns ET, Rennie PS, Cherkasov A.

Mol Cancer Ther. 2013 Nov;12(11):2425-35. doi: 10.1158/1535-7163.MCT-13-0267. Epub 2013 Aug 12.

5.

Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.

Munuganti RS, Leblanc E, Axerio-Cilies P, Labriere C, Frewin K, Singh K, Hassona MD, Lack NA, Li H, Ban F, Tomlinson Guns E, Young R, Rennie PS, Cherkasov A.

J Med Chem. 2013 Feb 14;56(3):1136-48. doi: 10.1021/jm3015712. Epub 2013 Jan 18.

PMID:
23301637
6.

Rac-induced left ventricular dilation in thyroxin-treated ZmRacD transgenic mice: role of cardiomyocyte apoptosis and myocardial fibrosis.

Elnakish MT, Hassona MD, Alhaj MA, Moldovan L, Janssen PM, Khan M, Hassanain HH.

PLoS One. 2012;7(8):e42500. doi: 10.1371/journal.pone.0042500. Epub 2012 Aug 24.

7.

Cardiac remodeling caused by transgenic overexpression of a corn Rac gene.

Elnakish MT, Awad MM, Hassona MD, Alhaj MA, Kulkarni A, Citro LA, Sayyid M, Abouelnaga ZA, El-Sayed O, Kuppusamy P, Moldovan L, Khan M, Hassanain HH.

Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H868-80. doi: 10.1152/ajpheart.00807.2010. Epub 2011 May 27.

8.

The effect of selective antihypertensive drugs on the vascular remodeling-associated hypertension: insights from a profilin1 transgenic mouse model.

Hassona MD, Elnakish MT, Abouelnaga ZA, Alhaj M, Wani AA, Hassanain H.

J Cardiovasc Pharmacol. 2011 May;57(5):550-8. doi: 10.1097/FJC.0b013e318212b1c2.

PMID:
21326111
9.

Vascular hypertrophy-associated hypertension of profilin1 transgenic mouse model leads to functional remodeling of peripheral arteries.

Hassona MD, Abouelnaga ZA, Elnakish MT, Awad MM, Alhaj M, Goldschmidt-Clermont PJ, Hassanain H.

Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H2112-20. doi: 10.1152/ajpheart.00016.2010. Epub 2010 Apr 16.

10.

Vascular hypertrophy and hypertension caused by transgenic overexpression of profilin 1.

Moustafa-Bayoumi M, Alhaj MA, El-Sayed O, Wisel S, Chotani MA, Abouelnaga ZA, Hassona MD, Rigatto K, Morris M, Nuovo G, Zweier JL, Goldschmidt-Clermont P, Hassanain H.

J Biol Chem. 2007 Dec 28;282(52):37632-9. Epub 2007 Oct 16.

Supplemental Content

Loading ...
Support Center